Skip to main content
Assets
Pfizer logo
PFE.NYSE
Pfizer
Health Care · Pharmaceuticals

Global pharmaceutical company developing vaccines and medicines for oncology, inflammation, cardiovascular, and rare diseases including COVID-19 vaccine.

HQ: United StatesListed: United States

Historical AI Opinions

Audit every published iPulse AI forecast batch and immutable historical research document for Pfizer.

Historical AI Opinions

Pfizer Inc. (PFE.NYSE) AI OPINIONS & ADVISOR ANALYSIS

Read the selected AI Advisor’s complete report, scenarios and forecast. Select Consensus for its investment thesis and a preview of advisor weights. Eligible access unlocks all 12 advisor reports and comparisons.

Updated on 28 November 2025Deep analysis 28 November 2025

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts
AI ResearcherAdvisor config deprecated

Investment Expert AI

Investment framework Framework

Model rating

Buy

5-Year Return Est.

+88.9%

Includes 4.38% annual net dividend contribution

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.18.0729.7541.4353.1164.79Nov 2020May 2023Nov 2025May 2028Nov 2030Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.
Quarterly Events ForecastPrice targets, total returns and complete scenario reasoning

Forecast prices in USD. Returns are cumulative from the forecast anchor. Swipe horizontally to read every column.

QuarterForecastTotal returnScenario
$27.1+5.6%Not Generated this time
$28.4+10.5%Not Generated this time
$29.8+16.1%Not Generated this time
$31.2+21.3%Not Generated this time
$32.5+26.4%Not Generated this time
$33.7+31.2%Not Generated this time
$35.1+36.5%Not Generated this time
$36.4+41.5%Not Generated this time
$37.8+46.9%Not Generated this time
$39.2+52.5%Not Generated this time
ADVISOR CONFIGURATION DEPRECATED

1. Investment Thesis — Base Case

The most reasonable thesis projects a stabilization and gradual recovery. While the COVID-19 revenue boom has evaporated and patent cliffs for major blockbusters like Ibrance and Eliquis present significant headwinds between 2026 and 2028, Pfizer's massive scale, aggressive cost-cutting, and the accretive revenue from Seagen provide a solid floor. The stock is currently priced for zero growth; therefore, modest pipeline successes in oncology and immunology, combined with a secure and attractive dividend yield (~5-6%), will drive total returns. We expect the stock to grind higher as earnings quality improves and the market digests the post-COVID reset, re-rating slowly from depressed levels to a fair value range of 12x-13x forward earnings by 2030.

2. Scenarios & Signals

2.1. Bull Case

In the bull case, Pfizer successfully executes its 'oncology pivot' following the Seagen integration, with the cancer portfolio delivering double-digit growth that significantly outweighs the impact of patent expirations for Ibrance and Eliquis. The company's pipeline delivers a best-in-class oral GLP-1 or similar metabolic asset, re-rating the stock to peer multiples closer to 15x-16x P/E. Cost realignment programs exceed targets, boosting operating margins back above 35%. Macroeconomically, a lower interest rate environment in 2026-2028 drives investors back to high-yield defensive stocks, compressing Pfizer's dividend yield and driving capital appreciation. By 2030, Pfizer re-establishes itself as a growth pharmaceutical company rather than a yield trap.

2.2. Bear Case

The bear case assumes the 'patent cliff' (Loss of Exclusivity for Eliquis, Ibrance, Xeljanz) erodes revenue faster than the pipeline can replenish it. The Seagen acquisition fails to generate expected return on invested capital due to competitive pressure in the ADC (Antibody-Drug Conjugate) space. Pfizer's attempts to enter the obesity market fail clinically or commercially. Legal liabilities related to legacy products or new unforeseen litigation weigh on cash flow, forcing a dividend cut or suspension of buybacks. Persistently high inflation or interest rates make risk-free bonds more attractive than Pfizer's dividend, causing the stock to de-rate to historically low multiples (8x-9x P/E) and languish in the low $20s or teens.

4. References & Context

Search behavior, retained evidence, supplied context, and response token details.
Prompt Tokens: 530Thinking Tokens: 2,263Response Tokens: 7,378Total Tokens: 10,171
Researcher modeSearch enabled · not used

This run was configured as Researcher, but no external search activity was recorded. The model proceeded from the supplied context as sufficient, effectively following a Thinker-style workflow.

Context supplied to the model

Public-safe inputs retained with this immutable forecast publication.

  1. 01

    Market data

    Input Prompt Market Equity Balanced Equity H5y S6m Brief Invest Thesis Ts Num Rsk Drv Var1

  2. 02

    Global context in this run

    Not used

  3. 03

    Fundamental data in this run

    Not used

  4. 04

    Forecast output requested

    Output Json Equity H5y S6m Brief Invest Thesis Ts Num Rsk Drv Var1

Original published forecast

Inspect the original revision and sealed receipt when a public record is available. Integrity verification is separate from forecast accuracy.

Research datasets created by iPulse AI and published by Future Edge Group FZE. Use is subject to the iPulse AI Terms of Service and applicable source rights.